Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 34
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early-Stage Breast Cancer Detection in Breast Milk

  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Ortiz, Carolina|||0000-0002-5523-829X
  • Matito, Judit|||0000-0001-7560-7737
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Suñol Camas, Anna
  • Martín, Ágatha|||0000-0003-4818-6433
  • Cordoba Cardona, Octavi|||0000-0002-9591-7430
  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Garcia-Ruiz, Itziar|||0000-0002-0717-7795
  • Miranda, Ignacio|||0000-0002-4813-5946
  • Morales-Comas, Clara|||0000-0001-6771-6749
  • Carrasco, Estela|||0000-0003-1964-7675
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Peg, Vicente|||0000-0002-5203-6166
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Bayó-Puxan, Neus|||0000-0001-9909-1499
  • González Medina, Alberto, 1990-|||0000-0002-2819-9053
  • Miquel, Josep M.|||0000-0002-9262-4464
  • Gómez-Rey, Marina|||0000-0002-9636-3281
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Arévalo, Silvia|||0000-0001-8169-1322
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Tabernero, Josep|||0000-0002-2495-8139
  • Vivancos, Ana|||0000-0003-2888-6512
  • Sansó, Miriam|||0000-0001-7155-4041
The presence of cell-free tumor DNA was reported in breast milk from patients with breast cancer, and its use as a screening method surpassed plasma liquid biopsy in terms of detecting and molecularly profiling early-stage tumors, even prior to diagnosis. For the first time, we show that BM obtained from patients with breast cancer carries ctDNA, surpassing plasma-based liquid biopsy for detection and molecular profiling of early-stage breast cancer, even prior to diagnosis by image.
Repisalud
Publicación Artículo científico (JournalArticle)

High Plasma Levels of sTNF-R1 and CCL11 Are Related to CD4+ T-Cells Fall in Human Immunodeficiency Virus Elite Controllers With a Sustained Virologic Control

  • Gutiirrez-Rivas, Monica
  • Jimenez-Sousa, Maria Angeles
  • Rallón, Norma
  • Jiménez, José Luis
  • Restrepo, Clara
  • León, Agathe
  • Montero-Alonso, Marta
  • González-García, Juan
  • Muñoz-Fernández, María Ángeles
  • Benito, José Miguel
  • Resino, Salvador
Our aim was to analyze the relationship between plasma inflammatory biomarkers and CD4+ T-cells evolution in human immunodeficiency virus (HIV) elite controllers (HIV-ECs) with a suppressed viremia. We carried out a retrospective study in 30 HIV-ECs classified into two groups: those showing no significant loss of CD4+ T-cells during the observation period (stable CD4+, n = 19) and those showing a significant decrease of CD4+ T-cells (decline CD4+, n = 11). Baseline plasma biomarkers were measured using a multiplex immunoassay: sTNF-R1, TRAIL, sFas (APO), sFasL, TNF-α, TNF-β, IL-8, IL-18, IL-6, IL-10, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, SDF1α, GRO-α, and CCL11. Baseline levels of sTNF-R1 and CCL11 and sTNF-R1/TNF-α ratio correlated with the slope of CD4+ T-cells (cells/μl/year) during follow-up [r = -0.370 (p = 0.043), r = -0.314 (p = 0.091), and r = -0.381 (p = 0.038); respectively]. HIV-ECs with declining CD4+ T-cells had higher baseline plasma levels of sTNF-R1 [1,500.7 (555.7; 2,060.7) pg/ml vs. 450.8 (227.9; 1,263.9) pg/ml; p = 0.018] and CCL11 [29.8 (23.5; 54.9) vs. 19.2 (17.8; 29.9) pg/ml; p = 0.041], and sTNF-R1/TNF-α ratio [84.7 (33.2; 124.2) vs. 25.9 (16.3; 75.1); p = 0.012] than HIV-1 ECs with stable CD4+ T-cells. The area under the receiver operating characteristic (ROC) curve [area under ROC curve (AUROC)] were 0.758 ± 0.093 (sTNF-R1), 0.727 ± 0.096 (CCL11), and 0.777 ± 0.087 (sTNF-R1/TNF-α). The cut-off of 75th percentile (high values) for these biomarkers had 71.4% positive predictive value and 73.9% negative predictive value for anticipating the evolution of CD4+ T-cells. In conclusion, the loss of CD4+ T-cells in HIV-ECs was associated with higher levels of two plasma inflammatory biomarkers (sTNF-R1 and CCL11), which were also reasonably accurate for the prediction of the CD4+ T-cells loss.
Repisalud
Publicación Artículo científico (JournalArticle)

CD32 Expression is not Associated to HIV-DNA content in CD4 cell subsets of individuals with Different Levels of HIV Control

  • GarcÍa, Marcial
  • Navarrete-Muñoz, Maria Angeles
  • Ligos, Jose M.
  • Cabello, Alfonso
  • Restrepo, Clara
  • Lopez-Bernaldo, Juan Carlos
  • de la Hera, Francisco Javier
  • Barros, Carlos
  • Montoya, Maria
  • Fernandez-Guerrero, Manuel
  • Estrada, Vicente
  • Gorgolas, Miguel
  • Benito, José Miguel
  • Rallon, Norma
A recent study has pointed out to CD32a as a potential biomarker of HIV-persistent CD4 cells. We have characterized the level and phenotype of CD32+ cells contained in different subsets of CD4 T-cells and its potential correlation with level of total HIV-DNA in thirty HIV patients (10 typical progressors naive for cART, 10 cART-suppressed patients, and 10 elite controllers). Total HIV-DNA was quantified in different subsets of CD4 T-cells: Trm and pTfh cells. Level and immunephenotype of CD32+ cells were analyzed in these same subsets by flow cytometry. CD32 expression in Trm and pTfh subsets was similar in the different groups, and there was no significant correlation between the level of total HIV-DNA and the level of CD32 expression in these subsets. However, total HIV-DNA level was correlated with expression of CD127 (rho = -0.46, p = 0.043) and of CCR6 (rho = -0.418, p = 0.027) on CD32+ cells. Our results do not support CD32 as a biomarker of total HIV-DNA content. However, analyzing the expression of certain markers by CD32+ cells could improve the utility of this marker in the clinical setting, prompting the necessity of further studies to both validate our results and to explore the potential utility of certain markers expressed by CD32+ cells.
Repisalud
Publicación Artículo científico (JournalArticle)

Peripheral T follicular helper Cells Make a Difference in HIV Reservoir Size between Elite Controllers and Patients on Successful cART

  • García, Marcial
  • Górgolas, Miguel
  • Cabello, Alfonso
  • Estrada, Vicente
  • Ligos, Jose M.
  • Fernández-Guerrero, Manuel
  • Barros, Carlos
  • López-Bernaldo, Juan Carlos
  • De La Hera, Francisco Javier
  • Montoya, Maria
  • Benito, José Miguel
  • Rallón, Norma
HIV latency is the main barrier to HIV eradication. Peripheral T follicular helper (pTfh) cells have a prominent role in HIV persistence. Herein, we analyzed the HIV reservoir size within memory CD4+ T-cell subsets in patients with HIV replication control. Twenty HIV-infected patients with suppressed HIV replication were included, with 10 elite controllers (EC) and 10 treated (TX) individuals. The HIV reservoir size was analyzed in resting memory CD4+ T-cells (Trm), pTfh, and non-pTfh cells using an ultrasensitive digital-droplet-PCR assay. Inter-group and intra-group differences were tested using non-parametric tests. Compared with the TX patients, the EC patients had smaller HIV reservoir not only in Trm but also in pTfh and non-pTfh subsets of memory CD4+ T-cells. The largest differences were observed in pTfh cells (p = 0.025). The pTfh and non-pTfh cells harbored similar levels of HIV-DNA in the EC (p = 0.60) and TX patients (p = 0.17); however, the contribution to HIV-DNA levels in memory CD4+ T-cells varied among the pTfh and non-pTfh subsets in both groups of patients. The EC patients showed smaller HIV reservoir in memory CD4+ cells, especially in the pTfh subset, a population of cells with a pivotal role in the antiviral immune response, suggesting a potential link between low levels of infection in pTfh cells and the ability of the EC patients to spontaneously control HIV replication.
Repisalud
Publicación Artículo científico (JournalArticle)

Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy

  • Medrano, Luz Maria
  • Gutiirrez-Rivas, Monica
  • Blanco, Julià
  • García, Marcial
  • Jimenez-Sousa, Maria Angeles
  • Pacheco, Yolanda María
  • Montero, Marta
  • Iribarren, José Antonio
  • Bernal, Enrique
  • Martínez, Onofre Juan
  • Benito, José Miguel
  • Rallón, Norma
  • Resino, Salvador
BACKGROUND: The mitochondrial DNA (mtDNA) seems to influence in a large number of diseases, including HIV infection. Moreover, there is a substantial inter-individual variability in the CD4+ recovery in HIV-infected patients on combination antiretroviral therapy (cART). Our study aimed to analyze the association between mtDNA haplogroups and CD4+ recovery in HIV-infected patients on cART. METHODS: This is a retrospective study of 324 naïve cART patients with CD4+ < 200 cells/mm3, who were followed-up during 24 months after initiating cART. All patients had undetectable HIV viral load during the follow-up. Besides, we included 141 healthy controls. MtDNA genotyping was performed by using Sequenom's MassARRAY platform. The primary outcome variable was the slope of CD4+ recovery. Patients were stratified into two groups by the median slope value of CD4+ (9.65 CD4+ cells/mm3/month). Logistic regression analyses were performed to calculate the odds of CD4+ recovery according to mtDNA haplogroups. RESULTS: Our study included European HIV-infected patients within the N macro-cluster. The baseline values of CD4+ T-cells were similar between groups of patients stratified by the P50th of the slope of CD4+ T-cells recovery. Patients in the low CD4+ T-cells recovery group were older (p = 0.001), but this variable was included in the multivariate models. When we analyzed the frequencies of mtDNA haplogroups, no significant differences between HIV-infected individuals and healthy controls were found. We did not find any significant association between mtDNA haplogroups and the slope of CD4+ T-cells recovery by linear regression analysis. However, Patients carrying haplogroup H had a higher odds of having a better CD4+ recovery (> 9.65 CD4+ cells/mm3/month) than patients without haplogroup H (p = 0.032). The adjusted logistic regression showed that patients carrying haplogroup H had a higher likelihood of achieving a CD4+ recovery > 9.65 CD4+ cells/mm3/month [adjusted odds ratio (aOR) = 1.75 (95% CI = 1.04; 2.95); p = 0.035]. CONCLUSIONS: European mitochondrial haplogroup H was associated with the improved CD4+ recovery in HIV-infected patients starting cART with CD4+ < 200 cells/mm3.
Repisalud
Publicación Artículo científico (JournalArticle)

IL7RA rs6897932 Polymorphism is Associated with Better CD4+ T-Cell Recovery in HIV Infected Patients Starting Combination Antiretroviral Therapy

  • Resino, Salvador
  • Navarrete-Muñoz, María A
  • Blanco, Julià
  • Pacheco, Yolanda María
  • Castro, Iván
  • Berenguer, Juan
  • Santos, Jesús
  • Vera-Méndez, Francisco J
  • Górgolas, Miguel
  • Jimenez-Sousa, Maria Angeles
  • Benito, José Miguel
  • Rallón, Norma
Interleukin-7 receptor subunit alpha (IL7RA) rs6897932 polymorphism is related to CD4+ recovery after combination antiretroviral therapy (cART), but no studies so far have analyzed its potential impact in patients with very low CD4+ T-cells count. We aimed to analyze the association between IL7RA rs6897932 polymorphism and CD4+ T-cells count restoration in HIV-infected patients starting combination antiretroviral therapy (cART) with CD4+ T-cells count <200 cells/mm3. We performed a retrospective study in 411 patients followed for 24 months with a DNA sample available for genotyping. The change in CD4+ T-cells count during the follow-up was considered as the primary outcome. The rs6897932 polymorphism had a minimum allele frequency (MAF) >20% and was in Hardy-Weinberg equilibrium (p = 0.550). Of 411 patients, 256 carried the CC genotype, while 155 had the CT/TT genotype. The CT/TT genotype was associated with a higher slope of CD4+ T-cells recovery (arithmetic mean ratio; AMR = 1.16; p = 0.016), higher CD4+ T-cells increase (AMR = 1.19; p = 0.004), and higher CD4+ T-cells count at the end of follow-up (AMR = 1.13; p = 0.006). Besides, rs6897932 CT/TT was related to a higher odds of having a value of CD4+ T-cells at the end of follow-up ≥500 CD4+ cells/mm3 (OR = 2.44; p = 0.006). After multiple testing correction (Benjamini-Hochberg), only the increase of ≥ 400 CD4+ cells/mm3 lost statistical significance (p = 0.052). IL7RA rs6897932 CT/TT genotype was related to a better CD4+ T-cells recovery and it could be used to improve the management of HIV-infected patients starting cART with CD4+ T-cells count <200 cells/mm3.
Repisalud
Publicación Artículo científico (JournalArticle)

HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study

  • Lopez-Huertas, Maria Rosa
  • Palladino, Claudia
  • Garrido-Arquero, Marta
  • Esteban-Cartelle, Beatriz
  • Sanchez-Carrillo, Marta
  • Martinez-Roman, Paula
  • Martín-Carbonero, Luz
  • Ryan, Pablo
  • Domínguez-Domínguez, Lourdes
  • de Los Santos, Ignacio
  • De La Fuente Moral, Sara
  • Benito, José Miguel
  • Rallón, Norma
  • Alcamí, José
  • Resino, Salvador
  • Fernandez-Rodriguez, Amanda
  • Coiras, Mayte
  • Briz, Veronica
In HIV-1/HCV-coinfected patients, chronic HCV infection leads to an increased T-lymphocyte immune activation compared to HIV-monoinfected patients, thereby likely contributing to increase HIV-1 reservoir that is the major barrier for its eradication. Our objective was to evaluate the influence of HCV coinfection in HIV-1 viral reservoir size in resting (r) CD4+ T-cells (CD25-CD69-HLADR-). Multicenter cross-sectional study of 97 cART-treated HIV-1 patients, including 36 patients with HIV and HCV-chronic co-infection without anti-HCV treatment, 32 HIV patients with HCV spontaneous clearance and 29 HIV-monoinfected patients. rCD4+ T-cells were isolated and total DNA was extracted. HIV viral reservoir was measured by Alu-LTR qPCR. Differences between groups were calculated with a generalized linear model. Overall, 63.9% were men, median age of 41 years and Caucasian. Median CD4+ and CD8+ T-lymphocytes were 725 and 858 cells/mm3, respectively. CD4+ T nadir cells was 305 cells/mm3. Proviral HIV-1 DNA size was significantly increased in chronic HIV/HCV-coinfected compared to HIV-monoinfected patients (206.21 ± 47.38 vs. 87.34 ± 22.46, respectively; P = 0.009), as well as in spontaneously clarified HCV co-infected patients when compared to HIV-monoinfected individuals (136.20 ± 33.20; P = 0.009). HIV-1/HCV co-infected patients showed a larger HIV-1 reservoir size in comparison to HIV-monoinfected individuals. This increase could lead to a greater complexity in the elimination of HIV-1 reservoir in HIV-1/HCV-coinfected individuals, which should be considered in the current strategies for the elimination of HIV-1 reservoir.
Repisalud
Publicación Artículo científico (JournalArticle)

Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count

  • Ruiz-de-León, María J
  • Jimenez-Sousa, Maria Angeles
  • Moreno, Santiago
  • García, Marcial
  • Gutiirrez-Rivas, Monica
  • León, Agathe
  • Montero-Alonso, Marta
  • González-García, Juan
  • Resino, Salvador
  • Rallón, Norma
  • Benito, José Miguel
  • Vallejo, Alejandro
  • ECRIS Network integrated in the Spanish AIDS Research Network
  • Briz, Veronica
  • Vázquez-Morón, Sonia
  • Fernández, A
  • García, P
  • Pernas, Maria
  • Casado, Concepcion
  • López, C
  • Capa, Laura
  • Pérez, M
  • Alcamí, José
Exosome-derived miR-21 was independently associated with CD4 T cell decline in HIV-1-infected elite controllers (OR 0.369, 95% CI 0.137-0.994, p = 0.049). Also, a negative correlation between miR-21 expression and MCP-1 level was found (r = -0.649, p = 0.020), while no correlation between soluble biomarkers or cellular immune activation was found.
Repisalud
Publicación Artículo científico (JournalArticle)

Genetic variation in CCR2 and CXCL12 genes impacts on CD4 restoration in patients initiating cART with advanced immunesupression

  • Restrepo, Clara
  • Gutiirrez-Rivas, Monica
  • Pacheco, Yolanda María
  • García, Marcial
  • Blanco, Julià
  • Medrano, Luz Maria
  • Navarrete-Muñoz, María A
  • Gutiérrez, Félix
  • Miralles, Pilar
  • Dalmau, David
  • Gómez, Juan Luis
  • Górgolas, Miguel
  • Cabello, Alfonso
  • Resino, Salvador
  • Benito, José Miguel
  • Rallón, Norma
OBJECTIVE: We investigated the association of genetic polymorphisms in chemokine and chemokine receptor genes with poor immunological recovery in HIV patients starting combined antiretroviral therapy (cART) with low CD4 T-cell counts. METHODS: A case-control study was conducted in 412 HIV-infected patients starting cART with CD4 T-cell count <200 cells/μL and successful viral control for two years. CD4 count increase below 200 cells/μL after two years on cART was used to define INR (immunological non-responder) patients. Polymorphisms in CXCL12, CCL5 and CCR2 genes were genotyped using sequenom's MassARRAY platform. RESULTS: Thirty two percent (134/412) of patients were classified as INR. After adjusting by age, route of HIV infection, length of infection before cART and viral hepatitis coinfection, CCR2 rs1799864-AG genotype was significantly associated with INR status (OR [95% CI]: 1.80 [1.04-3.11]; p = 0.04), and CXCL12 rs1801157-TT genotype showed a trend (OR [95% CI]: 2.47 [0.96-6.35]; p = 0.06). CONCLUSIONS: CCR2 rs1799864-AG or CXCL12 rs1801157-TT genotypes influence on the probability of poor CD4 recovery in the population of HIV patients starting cART with low CD4 counts. Genotyping of these polymorphisms could be used to estimate the risk of poor CD4 restoration, mainly in patients who are diagnosed late in the course of infection.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Search for Spatial Correlations of Neutrinos with Ultra-high-energy Cosmic Rays

  • Albert, A.
  • Alves, S.
  • Andre, M.
  • Anghinolfi, M.
  • Aubert,, J.J.
  • Aublin, J.
  • Baret, B.
  • Basa, S.
  • Belhorma, B.
  • Bendahman, M.
  • Bertin, V.
  • Biagi, S.
  • M. Bissinger
  • Martínez Mora, Juan Antonio
  • Poirè, Chiara
  • Ardid, Miguel|||0000-0002-3199-594X
  • Ardid, S.|||0000-0003-4821-6655
[EN] For several decades, the origin of ultra-high-energy cosmic rays (UHECRs) has been an unsolved question of high- energy astrophysics. One approach for solving this puzzle is to correlate UHECRs with high-energy neutrinos, since neutrinos are a direct probe of hadronic interactions of cosmic rays and are not de¿ected by magnetic ¿elds. In this paper, we present three different approaches for correlating the arrival directions of neutrinos with the arrival directions of UHECRs. The neutrino data are provided by the IceCube Neutrino Observatory and ANTARES, while the UHECR data with energies above ~50 EeV are provided by the Pierre Auger Observatory and the Telescope Array. All experiments provide increased statistics and improved reconstructions with respect to our previous results reported in 2015. The ¿rst analysis uses a high-statistics neutrino sample optimized for point- source searches to search for excesses of neutrino clustering in the vicinity of UHECR directions. The second analysis searches for an excess of UHECRs in the direction of the highest-energy neutrinos. The third analysis searches for an excess of pairs of UHECRs and highest-energy neutrinos on different angular scales. None of the analyses have found a signi¿cant excess, and previously reported over¿uctuations are reduced in signi¿cance. Based on these results, we further constrain the neutrino ¿ux spatially correlated with UHECRs., The authors of the ANTARES collaboration acknowledge the financial support of the funding agencies: Centre National de la Recherche Scientifique (CNRS), Commissariat a l'energie atomique et aux energies alternatives (CEA), Commission Europeenne (FEDER fund and Marie Curie Program), Institut Universitaire de France (IUF), LabEx UnivEarthS (ANR-10-LABX-0023 and ANR-18-IDEX-0001), Region Ile-de-France (DIM-ACAV), Region Alsace (contrat CPER), Region Provence-Alpes-Cote d'Azur, Departement du Var and Ville de La Seyne-sur-Mer, France; Bundesministerium fur Bildung und Forschung (BMBF), Germany; Istituto Nazionale di Fisica Nucleare (INFN), Italy; Nederlandse organisatie voor Wetenschappelijk Onderzoek (NWO), the Netherlands; Council of the President of the Russian Federation for young scientists and leading scientific schools supporting grants, Russia; Executive Unit for Financing Higher Education, Research, Development and Innovation (UEFISCDI), Romania; Ministerio de Ciencia, Innovacion, Investigacion y Universidades (MCIU): Programa Estatal de Generacion de Conocimiento (refs. PGC2018-096663-B-C41, -A-C42, -B-C43, -B-C44) (MCIU/FEDER), Generalitat Valenciana: Prometeo (PROMETEO/2020/019), Grisolia (refs. GRISOLIA/2018/119,/2021/192) and GenT (refs. CIDEGENT/2018/034,/2019/043,/2020/049,/2021/023) programs, Junta de Andalucia (ref. A-FQM-053-UGR18), La Caixa Foundation (ref. LCF/BQ/IN17/11620019), EU: MSC program (ref. 101025085), Spain; Ministry of Higher Education, Scientific Research and Innovation, Morocco, and the Arab Fund for Economic and Social Development, Kuwait. We also acknowledge the technical support of Ifremer, AIM and Foselev Marine for the sea operation and the CC-IN2P3 for the computing facilities. The ANTARES collaboration acknowledges the significant contributions to this manuscript from Julien Aublin.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

The Role of PemIK (PemK/PemI) Type II TA System from Klebsiella pneumoniae Clinical Strains in Lytic Phage Infection

  • Bleriot Rial, Inés
  • Blasco, Lucía
  • Pacios Santamaría, Olga
  • Fernández-García, Laura
  • Ambroa, Antón
  • López Díaz, María
  • Ortiz-Cartagena, Concha
  • Fernández-Cuenca, Felipe
  • Oteo, Jesús
  • Pascual, Álvaro
  • Martínez-Martínez, Luis
  • Domingo-Calap, Pilar
  • Wood, Thomas K.
  • Tomás, María
[Abstract] Since their discovery, toxin-antitoxin (TA) systems have captivated the attention of many scientists. Recent studies have demonstrated that TA systems play a key role in phage inhibition. The aim of the present study was to investigate the role of the PemIK (PemK/PemI) type II TA system in phage inhibition by its intrinsic expression in clinical strains of Klebsiella pneumoniae carrying the lncL plasmid, which harbours the carbapenemase OXA-48 and the PemK/PemI TA system. Furthermore, induced expression of the system in an IPTG-inducible plasmid in a reference strain of K. pneumoniae ATCC10031 was also studied. The results showed that induced expression of the whole TA system did not inhibit phage infection, whereas overexpression of the pemK toxin prevented early infection. To investigate the molecular mechanism involved in the PemK toxin-mediated inhibition of phage infection, assays measuring metabolic activity and viability were performed, revealing that overexpression of the PemK toxin led to dormancy of the bacteria. Thus, we demonstrate that the PemK/PemI TA system plays a role in phage infection and that the action of the free toxin induces a dormant state in the cells, resulting in inhibition of phage infections., This study was funded by grant PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008-2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research—European Regional Development Fund "A way of Making Europe" and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0001, RD16/0016/0006 and RD16/CIII/0004/0002) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Programme (SERGAS and ISCIII). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). O. Pacios and M. López was financially supported by a grant IN606A-2020/035 and IN606B-2018/008, respectively (GAIN, Xunta de Galicia) and M. Gonzalez-Bardanca was financially supported by the Rio Hortega program (ISCIII, CM20/00198), Xunta de Galicia; IN606A-2020/035, Xunta de Galicia; IN606B-2018/008
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies

  • González de Aledo, Manuel
  • González-Bardanca, Mónica
  • Blasco, Lucía
  • Pacios Santamaría, Olga
  • Bleriot Rial, Inés
  • Fernández-García, Laura
  • Fernández-Quejo, Melisa
  • López Díaz, María
  • Bou, Germán
  • Tomás, María
This article belongs to the Special Issue Non-antimicrobial Agents as Adjuvants against Bacterial Infections, [Abstract] One of the biggest threats we face globally is the emergence of antimicrobial-resistant (AMR) bacteria, which runs in parallel with the lack in the development of new antimicrobials. Among these AMR bacteria pathogens belonging to the ESKAPE group can be highlighted (Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) due to their profile of drug resistance and virulence. Therefore, innovative lines of treatment must be developed for these bacteria. In this review, we summarize the different strategies for the treatment and study of molecular mechanisms of AMR in the ESKAPE pathogens based on the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins’ technologies: loss of plasmid or cellular viability, random mutation or gene deletion as well directed mutations that lead to a gene’s loss of function., This study was funded by grants PI16/01163 and PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research-European Regional Development Fund “A way of Making Europe” and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0006) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/, Accessed on 21 June 2021). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). O. Pacios and M. López was financially supported by a grant IN606A-2020/035 and IN606B-2018/008, respectively, (GAIN, Xunta de Galicia), and M. Gonzalez-Bardanca was financially supported by the Rio Hortega program (ISCIII, CM20/00198), Xunta de Galicia; IN606A-2020/035, Xunta de Galicia; IN606B-2018/008
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genome-wide transcriptome study in skin biopsies reveals an association of E2F4 with cadasil and cognitive impairment

  • Maisterra Santos, Olga
  • Jimenez Balado, Joan
  • Carrera, Caty
  • Torres‑Aguila, Nuria P.
  • Muiño, Elena
  • Cullell, Natalia
Demència; Mal de cap; Ictus, Demencia; Dolor de cabeza; Ictus, Dementia; Headache; Stroke, CADASIL is a small vessel disease caused by mutations in NOTCH3 that lead to an odd number of cysteines in the EGF-like repeat domain, causing protein misfolding and aggregation. The main symptoms are migraine, psychiatric disturbances, recurrent strokes and dementia, being executive function characteristically impaired. The molecular pathways altered by this receptor aggregation need to be studied further. A genome-wide transcriptome study (four cases paired with three healthy siblings) was carried out, in addition to a qRT-PCR for validation purposes (ten new cases and eight new controls). To study the expression profile by cell type of the significant mRNAs found, we performed an in situ hybridization (ISH) (nine cases and eight controls) and a research in the Single-nuclei Brain RNA-seq expression browser (SNBREB). Pathway analysis enrichment was carried out with Gene Ontology and Reactome. Neuropsychological tests were performed in five of the qRT-PCR cases. The two most significant differentially expressed mRNAs (BANP, p-value = 7.23 × 10–4 and PDCD6IP, p-value = 8.36 × 10–4) were selected for the validation study by qRT-PCR. Additionally, we selected two more mRNAs (CAMK2G, p-value = 4.52 × 10–3 and E2F4, p-value = 4.77 × 10–3) due to their association with ischemic neuronal death. E2F4 showed differential expression in the genome-wide transcriptome study and in the qRT-PCR (p = 1.23 × 10–3), and it was upregulated in CADASIL cases. Furthermore, higher E2F4 expression was associated with worse executive function (p = 2.04 × 10–2) and attention and information processing speed (IPS) (p = 8.73 × 10–2). In situ hibridization showed E2F4 expression in endothelial and vascular smooth vessel cells. In silico studies indicated that E2F4 is also expressed in brain endothelial cells. Among the most significant pathways analyzed, there was an enrichment of vascular development, cell adhesion and vesicular machinery terms and autophagy process. E2F4 is more highly expressed in the skin biopsy of CADASIL patients compared to controls, and its expression is present in endothelial cells and VSMCs. Further studies are needed to understand whether E2F4 could be useful as a biomarker, to monitor the disease or be used as a therapeutic target., This work was supported by a grant from the Carlos III Health Institute (PI 11/0176), Generación Project, Maestro Project, INVICTUS + network, Epigenesis Project (Marató de TV3), FEDER funds and economic donations from “Asociación CADASIL España”. E. Muiño is supported by a Río Hortega Contract (CM18/00198) from the Carlos III Health Institute. J. Cárcel-Márquez is supported by an AGAUR Contract (agència de gestió d'ajuts universitaris i de recerca; FI_DGR 2019, grant number 2019_FI_B 00853) co-financed with Fons Social Europeu (FSE). M. Lledós is supported by a PFIS Contract (Contratos Predoctorales de Formación en Investigación en Salud) from the Carlos III Health Institute.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The target antigen determines the mechanism of acquired resistance to T cell-based therapies

  • Morancho Armisen, Beatriz
  • Román Alonso, Macarena
  • Ovejero Romero, Pablo
  • Arribas López, Joaquin Vicente
  • Arenas Lahuerta, Enrique Javier
  • Martínez-Sabadell, Alex
  • Rius Ruiz, Irene
  • Escorihuela Baez, Marta
Cancer; Antigen; Resistance, Cáncer; Antígeno; Resistencia, Càncer; Antigen; Resistència, Despite the revolution of immunotherapy in cancer treatment, patients eventually progress due to the emergence of resistance. In this scenario, the selection of the tumor antigen can be decisive in the success of the clinical response. T cell bispecific antibodies (TCBs) are engineered molecules that include binding sites to the T cell receptor and to a tumor antigen. Using gastric CEA+/HER2+ MKN45 cells and TCBs directed against CEA or HER2, we show that the mechanism of resistance to a TCB is dependent on the tumor antigen. Acquired resistant models to a high-affinity-CEA-targeted TCB exhibit a reduction of CEA levels due to transcriptional silencing, which is reversible upon 5-AZA treatment. In contrast, a HER2-TCB resistant model maintains HER2 levels and exhibit a disruption of the interferon-gamma signaling. These results will help in the design of combinatorial strategies to increase the efficacy of cancer immunotherapies and to anticipate and overcome resistances., This work was supported by Asociación Española Contra el Cancer (AECC), Breast Cancer Research Foundation (BCRF-21-008), and Instituto de Salud Carlos III (PI19/01181). A.M.S. was funded by the Spanish Government (PFIS FI20/00188). B.M. was funded by a fellowship from PERIS (Departament de Salut, Generalitat de Catalunya). M.R.A. was funded by Agency for Management of University and Research Grants (AGAUR, 2022 FI_B2 00080). P.O.R. was funded by the BBVA. E.J.A. was funded by the AECC (POSTD211413AREN). VHIO acknowledges the Cellex Foundation for providing research facilities and equipment, the Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) from the Institute of Health Carlos III (ISCIII), and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 SLT008/18/00205) for their support on this research. The authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S/AEI/10.13039/501100011033) and for the Cancer Immunology and Immunotherapy (CAIMI-2) program funded by BBVA Foundation. We would like to remark the funding from B.M PERIS (Spain). The authors thank Dr. Anne Freimoser-Grundschober and Roche for helping provide the TCBs. The graphical abstract was created with BioRender.com.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

  • Ros Montañá, Fco. Javier
  • Fernández, Jose
  • Moreno-Cárdenas, Ana Belén
  • Arenillas Lallana, Carlota
  • Fasani, Roberta
  • Garcia Rodriguez, Ariadna
  • Gonzalo-Ruiz, Javier
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Pérez López, Raquel
  • Tabernero, Josep
  • De Almeida Toledo, Rodrigo
  • Comas Navarro, Raquel
  • Dienstmann, Rodrigo
  • Bernatowicz, Kinga
  • Piris-Giménez, Alejandro
  • Elez Fernandez, Mª Elena
  • Villacampa Javierre, Guillermo
Colorectal cancer; Predictive markers; Tumour biomarkers, Cáncer colorrectal; Marcadores predictivos; Biomarcadores tumorales, Càncer colorrectal; Marcadors predictius; Biomarcadors tumorals, Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients., VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the FERO Foundation for their funding support, the Consorcio Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, CB16/12/00259) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation, and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 and SLT008/18/00205) for their support on this research. Authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S / AEI / 10.13039 /501100011033). This research is funded by the SCITRON program; Novartis funded the genomics characterization by WES of samples from 28 patients from the discovery cohort and had no influence on data analysis/interpretation or writing of the paper (3003145512 to R.A.T.). S.Li. is financially supported by a Chinese Scholarship Council PhD fellowship (201909370083 to S. Li). R.P.-L. is supported by a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019 to R.P.-L.) and the Prostate Cancer Foundation (Young Investigator Award). This work was supported by the Miguel Servet-I Research Award from ISCIII of the Ministry of Economy (CP17/00199 to R.A.T.), the Olga Torres Foundation Award to emerging researchers (2601 to R.A.T.), the ISCIII-FEDER (PI17/00947 and PI20/00968 to E.E.), and the Fundación AECC (CLSEN19001ELEZ to E.E.) and Ministry of Science and Innovation (Europa Redes y Gestores, ECT2020-000827 to E.E.).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Phosphatidylserine-liposomes promote tolerogenic features on dendritic cells in human type 1 diabetes by apoptotic mimicry

  • Rodriguez Fernandez, Silvia
  • Pujol-Autonell, Irma|||0000-0001-6086-4183
  • Brianso, Ferran
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • García Jimeno, Sonia|||0000-0003-3821-2714
  • Villalba Felipe, Adrián|||0000-0003-3148-5453
  • Sánchez, Alex|||0000-0002-8673-7737
  • Aguilera, Eva|||0000-0002-0164-4006
  • Vázquez, Federico|||0000-0001-6493-2374
  • Verdaguer, Joan
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Vives Pi, Marta|||0000-0003-3735-0779
Type 1 diabetes (T1D) is a metabolic disease caused by the autoimmune destruction of insulin-producing β-cells. With its incidence increasing worldwide, to find a safe approach to permanently cease autoimmunity and allow β-cell recovery has become vital. Relying on the inherent ability of apoptotic cells to induce immunological tolerance, we demonstrated that liposomes mimicking apoptotic β-cells arrested autoimmunity to β-cells and prevented experimental T1D through tolerogenic dendritic cell (DC) generation. These liposomes contained phosphatidylserine (PS)-the main signal of the apoptotic cell membrane-and β-cell autoantigens. To move toward a clinical application, PS-liposomes with optimum size and composition for phagocytosis were loaded with human insulin peptides and tested on DCs from patients with T1D and control age-related subjects. PS accelerated phagocytosis of liposomes with a dynamic typical of apoptotic cell clearance, preserving DCs viability. After PS-liposomes phagocytosis, the expression pattern of molecules involved in efferocytosis, antigen presentation, immunoregulation, and activation in DCs concurred with a tolerogenic functionality, both in patients and control subjects. Furthermore, DCs exposed to PS-liposomes displayed decreased ability to stimulate autologous T cell proliferation. Moreover, transcriptional changes in DCs from patients with T1D after PS-liposomes phagocytosis pointed to an immunoregulatory prolife. Bioinformatics analysis showed 233 differentially expressed genes. Genes involved in antigen presentation were downregulated, whereas genes pertaining to tolerogenic/anti-inflammatory pathways were mostly upregulated. In conclusion, PS-liposomes phagocytosis mimics efferocytosis and leads to phenotypic and functional changes in human DCs, which are accountable for tolerance induction. The herein reported results reinforce the potential of this novel immunotherapy to re-establish immunological tolerance, opening the door to new therapeutic approaches in the field of autoimmunity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Liposome-based immunotherapy against autoimmune diseases, Therapeutic effect on multiple sclerosis

  • Pujol-Autonell, Irma|||0000-0001-6086-4183
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Rodríguez Fernández, Silvia
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Ampudia Carrasco, Rosa María|||0000-0002-0734-0433
  • Rius, Aleix
  • García Jimeno, Sonia|||0000-0003-3821-2714
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Vives Pi, Marta|||0000-0003-3735-0779
Based on the ability of apoptosis to induce immunological tolerance, liposomes were generated mimicking apoptotic cells, and they arrest autoimmunity in Type 1 diabetes. Our aim was to validate the immunotherapy in other autoimmune disease: multiple sclerosis. Materials & methods: Phosphatidylserine-rich liposomes were loaded with disease-specific autoantigen. Therapeutic capability of liposomes was assessed in vitro and in vivo. Results: Liposomes induced a tolerogenic phenotype in dendritic cells, and arrested autoimmunity, thus decreasing the incidence, delaying the onset and reducing the severity of experimental disease, correlating with an increase in a probably regulatory CD25+ FoxP3- CD4+ T-cell subset. Conclusion: This is the first work that confirms phosphatidylserine-liposomes as a powerful tool to arrest multiple sclerosis, demonstrating its relevance for clinical application.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential

  • Rodríguez Fernández, Silvia
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Villalba Felipe, Adrián|||0000-0003-3148-5453
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Gómez Muñoz, Laia|||0000-0001-9640-6213
  • Aguilera, Eva|||0000-0002-0164-4006
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Vázquez, Federico|||0000-0001-6493-2374
  • Bel, Joan|||0000-0002-3577-6322
  • Vives Pi, Marta|||0000-0003-3735-0779
Type 1 diabetes (T1D) is prompted by defective immunological tolerance, an event in which dendritic cells (DCs) are crucial as immune response orchestrators. In fact, they contribute to maintaining tolerance to self-antigens, but they can also prompt an immunogenic response against them, leading to autoimmunity. Countless factors can potentially impact on the proper functionality of the DCs, which range from altered subset distribution, impaired phagocytic function to abnormal gene expression. Moreover, in T1D, metabolic dysregulation could impair DC functions as well. Indeed, since T1D clinical course is likely to be more aggressive in children and adolescents and entails severe dysglycemia, the aim of this study was to analyze circulating DCs subpopulations in pediatric T1D at different stages, as well as to characterize their phagocytosis ability and tolerance induction potential. Thus, pediatric patients newly diagnosed with T1D, with established disease and control subjects were recruited. Firstly, DCs subsets from peripheral blood were found quantitatively altered during the first year of disease, but recovered in the second year of progression. Secondly, to study the tolerogenic functionality of DCs, liposomes with phosphatidylserine (PS) were designed to mimic apoptotic beta cells, which are able to induce tolerance, as previously demonstrated by our group in DCs from adult patients with T1D. In this study, monocyte-derived DCs from pediatric patients with T1D and control subjects were assessed in terms of PS-liposomes capture kinetics, and transcriptional and phenotypic changes. DCs from pediatric patients with T1D were found to phagocyte PS-liposomes more slowly and less efficiently than DCs from control subjects, inversely correlating with disease evolution. Nonetheless, the transcription of PS receptors and immunoregulatory genes, cytokine profile, and membrane expression of immunological markers in DCs was consistent with tolerogenic potential after PS-liposomes phagocytosis. In conclusion, T1D progression in childhood entails altered peripheral blood DCs subsets, as well as impaired DCs phagocytosis, although tolerance induction could still function optimally. Therefore, this study provides useful data for patient follow-up and stratification in immunotherapy clinical trials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acquired cold urticaria vs. Autoinflammatory diseases, genetic and clinical profile and differential diagnosis, Study of a cohort of patients in a tertiary reference centre

  • Deza, Gustavo
  • Mensa-Vilaro, Anna|||0000-0001-7541-9672
  • March-Rodriguez, Alvaro
  • Sánchez Pérez, Sílvia
  • Pujol Vallverdú, Ramón M.|||0000-0002-5622-6055
  • Aróstegui, Juan Ignacio|||0000-0003-4757-504X
  • Giménez-Arnau, Ana M.|||0000-0001-5434-7753
Acquired cold urticaria (ACU) is characterized by the development of itchy wheals after cold exposure. Generalized urticarial skin rashes triggered by cold exposure characterize certain monogenic autoinflammatory diseases (AIDs). The objective of this study is to investigate the presence of variants in genes causing AIDs that present with cold-induced urticarial skin rashes in patients clinically diagnosed with ACU, in order to look for susceptibility factors for the disease. Fifty patients with primary ACU were studied. Germline and post-zygotic variants on the NLRP3, NLRP12, NLRC4 and PLCG2 genes were investigated using nextgeneration sequencing technology. Seven patients (14%) carried 8 heterozygous germline variants in the following genes: NLRP3 (n = 1), NLRP12 (n = 3), NLRC4 (n = 1), PLCG2 (n = 3). No pathogenic or likely pathogenic variants were detected, and deep analyses of the sequences obtained did not identify any post-zygotic variant. In conclusion, ACU is not related to post-zygotic or germline pathogenic variants in the NLRP3, NLRP12, NLRC4 and PLCG2 genes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prenatal Betamethasone interferes with immune system development and alters target cells in autoimmune diabetes

  • Perna-Barrull, David|||0000-0003-2079-818X
  • Rodríguez-Fernández, Silvia|||0000-0001-8429-4293
  • Pujol-Autonell, Irma|||0000-0001-6086-4183
  • Gieras, Anna|||0000-0002-5147-2281
  • Ampudia Carrasco, Rosa María|||0000-0002-0734-0433
  • Villalba Felipe, Adrián|||0000-0003-3148-5453
  • Glau, Laura
  • Tolosa, Eva|||0000-0002-5247-8378
  • Vives Pi, Marta|||0000-0003-3735-0779
Non-genetic factors are crucial in the pathogenesis of type 1 diabetes (T1D), a disease caused by autoimmunity against insulin-producing β-cells. Exposure to medications in the prenatal period may influence the immune system maturation, thus altering self-tolerance. Prenatal administration of betamethasone -a synthetic glucocorticoid given to women at risk of preterm delivery- may affect the development of T1D. It has been previously demonstrated that prenatal betamethasone administration protects offspring from T1D development in nonobese diabetic (NOD) mice. The direct effect of betamethasone on the immature and mature immune system of NOD mice and on target β-cells is analysed in this paper. In vitro, betamethasone decreased lymphocyte viability and induced maturation-resistant dendritic cells, which in turn impaired γδ T cell proliferation and decreased IL-17 production. Prenatal betamethasone exposure caused thymus hypotrophy in newborn mice as well as alterations in immune cells subsets. Furthermore, betamethasone decreased β-cell growth, reduced C-peptide secretion and altered the expression of genes related to autoimmunity, metabolism and islet mass in T1D target tissue. These results support the protection against T1D in the betamethasone-treated offspring and demonstrate that this drug alters the developing immune system and β-cells. Understanding how betamethasone generates self-tolerance could have potential clinical relevance in T1D.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy

  • Medrano, Luz M.
  • Gutiérrez-Rivas, Mónica
  • Blanco, Julià|||0000-0002-2225-0217
  • García, Marcial
  • Jiménez-Sousa, María A.
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Montero, Marta|||0000-0002-3432-5394
  • Iribarren, José Antonio
  • Bernal, Enrique|||0000-0002-4041-0579
  • Martínez, Onofre Juan
  • Benito, José Miguel|||0000-0002-7172-049X
  • Rallón, Norma|||0000-0002-4643-247X
  • Resino, Salvador|||0000-0001-8783-0450
The mitochondrial DNA (mtDNA) seems to influence in a large number of diseases, including HIV infection. Moreover, there is a substantial inter-individual variability in the CD4+ recovery in HIV-infected patients on combination antiretroviral therapy (cART). Our study aimed to analyze the association between mtDNA haplogroups and CD4+ recovery in HIV-infected patients on cART. This is a retrospective study of 324 naïve cART patients with CD4+ < 200 cells/mm 3, who were followed-up during 24 months after initiating cART. All patients had undetectable HIV viral load during the follow-up. Besides, we included 141 healthy controls. MtDNA genotyping was performed by using Sequenom's MassARRAY platform. The primary outcome variable was the slope of CD4+ recovery. Patients were stratified into two groups by the median slope value of CD4+ (9.65 CD4+ cells/mm 3 /month). Logistic regression analyses were performed to calculate the odds of CD4+ recovery according to mtDNA haplogroups. Our study included European HIV-infected patients within the N macro-cluster. The baseline values of CD4+ T-cells were similar between groups of patients stratified by the P50th of the slope of CD4+ T-cells recovery. Patients in the low CD4+ T-cells recovery group were older (p = 0.001), but this variable was included in the multivariate models. When we analyzed the frequencies of mtDNA haplogroups, no significant differences between HIV-infected individuals and healthy controls were found. We did not find any significant association between mtDNA haplogroups and the slope of CD4+ T-cells recovery by linear regression analysis. However, Patients carrying haplogroup H had a higher odds of having a better CD4+ recovery (> 9.65 CD4+ cells/mm 3 /month) than patients without haplogroup H (p = 0.032). The adjusted logistic regression showed that patients carrying haplogroup H had a higher likelihood of achieving a CD4+ recovery > 9.65 CD4+ cells/mm 3 /month [adjusted odds ratio (aOR) = 1.75 (95% CI = 1.04; 2.95); p = 0.035]. European mitochondrial haplogroup H was associated with the improved CD4+ recovery in HIV-infected patients starting cART with CD4+ < 200 cells/mm 3.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-wide transcriptome study in skin biopsies reveals an association of E2F4 with cadasil and cognitive impairment

  • Muiño, Elena|||0000-0001-5839-7328
  • Maisterra Santos, Olga
  • Jiménez-Balado, Joan|||0000-0003-4125-9134
  • Cullell, Natalia|||0000-0001-5118-1014
  • Carrera, Caty|||0000-0002-0804-0969
  • Torres-Aguila, Nuria|||0000-0002-9502-9310
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Lledós, Miquel|||0000-0001-8832-789X
  • González-Sánchez, Jonathan
  • Olmos-Alpiste, Ferran|||0000-0003-1856-0391
  • Espejo, Eva
  • March, Álvaro
  • Pujol Vallverdú, Ramón M.|||0000-0002-5622-6055
  • Rodriguez Campello, Ana Maria|||0000-0001-8621-1420
  • Romeral, Gemma
  • Krupinski, Jurek
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Montaner, Joan|||0000-0003-4845-2279
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
CADASIL is a small vessel disease caused by mutations in NOTCH3 that lead to an odd number of cysteines in the EGF-like repeat domain, causing protein misfolding and aggregation. The main symptoms are migraine, psychiatric disturbances, recurrent strokes and dementia, being executive function characteristically impaired. The molecular pathways altered by this receptor aggregation need to be studied further. A genome-wide transcriptome study (four cases paired with three healthy siblings) was carried out, in addition to a qRT-PCR for validation purposes (ten new cases and eight new controls). To study the expression profile by cell type of the significant mRNAs found, we performed an in situ hybridization (ISH) (nine cases and eight controls) and a research in the Single-nuclei Brain RNA-seq expression browser (SNBREB). Pathway analysis enrichment was carried out with Gene Ontology and Reactome. Neuropsychological tests were performed in five of the qRT-PCR cases. The two most significant differentially expressed mRNAs (BANP, p-value = 7.23 × 10 -4 and PDCD6IP, p-value = 8.36 × 10 -4) were selected for the validation study by qRT-PCR. Additionally, we selected two more mRNAs (CAMK2G, p-value = 4.52 × 10 -3 and E2F4, p-value = 4.77 × 10 -3) due to their association with ischemic neuronal death. E2F4 showed differential expression in the genome-wide transcriptome study and in the qRT-PCR (p = 1.23 × 10 -3), and it was upregulated in CADASIL cases. Furthermore, higher E2F4 expression was associated with worse executive function (p = 2.04 × 10 -2) and attention and information processing speed (IPS) (p = 8.73 × 10 -2). In situ hibridization showed E2F4 expression in endothelial and vascular smooth vessel cells. In silico studies indicated that E2F4 is also expressed in brain endothelial cells. Among the most significant pathways analyzed, there was an enrichment of vascular development, cell adhesion and vesicular machinery terms and autophagy process. E2F4 is more highly expressed in the skin biopsy of CADASIL patients compared to controls, and its expression is present in endothelial cells and VSMCs. Further studies are needed to understand whether E2F4 could be useful as a biomarker, to monitor the disease or be used as a therapeutic target.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ICA1L Is Associated with Small Vessel Disease, A Proteome-Wide Association Study in Small Vessel Stroke and Intracerebral Haemorrhage

  • Cullell, Natalia|||0000-0001-5118-1014
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Muiño, Elena|||0000-0001-5839-7328
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Molina, Jessica
  • Casas, Laura
  • Almeria, Marta|||0000-0001-7445-6113
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Krupinski, Jerzy|||0000-0002-5136-8898
Small vessel strokes (SVS) and intracerebral haemorrhages (ICH) are acute outcomes of cerebral small vessel disease (SVD). Genetic studies combining both phenotypes have identified three loci associated with both traits. However, the genetic cis-regulation at the protein level associated with SVD has not been studied before. We performed a proteome-wide association study (PWAS) using FUSION to integrate a genome-wide association study (GWAS) and brain proteomic data to discover the common mechanisms regulating both SVS and ICH. Dorsolateral prefrontal cortex (dPFC) brain proteomes from the ROS/MAP study (N = 376 subjects and 1443 proteins) and the summary statistics for the SVS GWAS from the MEGASTROKE study (N = 237,511) and multi-trait analysis of GWAS (MTAG)-ICH-SVS from Chung et al. (N = 240,269) were selected. We performed PWAS and then a co-localization analysis with COLOC. The significant and nominal results were validated using a replication dPFC proteome (N = 152). The replicated results (q -value < 0.05) were further investigated for the causality relationship using summary data-based Mendelian randomization (SMR). One protein (ICA1L) was significantly associated with SVS (z-score = -4.42 and p -value = 9.6 × 10 -6) and non-lobar ICH (z-score = -4.8 and p -value = 1.58 × 10 -6) in the discovery PWAS, with a high co-localization posterior probability of 4. In the validation PWAS, ICA1L remained significantly associated with both traits. The SMR results for ICA1L indicated a causal association of protein expression levels in the brain with SVS (p -value = 3.66 × 10 -5) and non-lobar ICH (p -value = 1.81 × 10 -5). Our results show that the association of ICA1L with SVS and non-lobar ICH is conditioned by the cis-regulation of its protein levels in the brain.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sleep/wake cycle alterations as a cause of neurodegenerative diseases, A Mendelian randomization study

  • Cullell, Natalia|||0000-0001-5118-1014
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Muiño, Elena|||0000-0001-5839-7328
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Amaut, K.E.U.
  • Krupinski, J.
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Sleep and/or wake cycle alterations are common in neurodegenerative diseases (ND). Our aim was to determine whether there is a causal relationship between sleep and/or wake cycle patterns and ND (Parkinson's disease (PD) age at onset (AAO), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS)) using two-sample Mendelian Randomization (MR). We selected 12 sleep traits with available Genome-Wide Association Study (GWAS) to evaluate their causal relationship with the ND risk through Inverse-Variance Weighted regression as main analysis. We used as outcome the latest ND GWAS with available summary-statistics: PD-AAO (N = 17,996), AD (N = 21,235) and ALS (N = 40,136). MR results pointed to a causal effect of subjective and objective-measured morning chronotype on later PD-AAO (95%CI:0.33-1.81, p = 8.47×10 and 95%CI:-7.28 to -4.44, p = 5.87×10, respectively). Sleep efficiency was causally associated with a decreased AD risk (95%CI:-20.408 to -0.66, p = 0.04) and daytime sleepiness with an increased ALS risk (95%CI:0.15 to 1.61, p = 0.01). Our study suggests that sleep and/or wake patterns have causal relationship with ND. Given that sleep and/or wake patterns are modifiable risk factors, sleep interventions should be investigated as a potential treatment in PD-AAO, AD and ALS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Contribution of "Omic" studies to the understanding of CADASIL. A systematic review

  • Muiño, Elena|||0000-0001-5839-7328
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Arboix, Adrià|||0000-0002-8512-7881
CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a small vessel disease caused by mutations in NOTCH3 that lead to an odd number of cysteines in the epidermal growth factor (EGF)-like repeat domain, causing protein misfolding and aggregation. The main symptoms are migraines, psychiatric disorders, recurrent strokes, and dementia. Omic technologies allow the massive study of different molecules for understanding diseases in a non-biased manner or even for discovering targets and their possible treatments. We analyzed the progress in understanding CADASIL that has been made possible by omics sciences. For this purpose, we included studies that focused on CADASIL and used omics techniques, searching bibliographic resources, such as PubMed. We excluded studies with other phenotypes, such as migraine or leukodystrophies. A total of 18 articles were reviewed. Due to the high prevalence of NOTCH3 mutations considered pathogenic to date in genomic repositories, one can ask whether all of them produce CADASIL, different degrees of the disease, or whether they are just a risk factor for small vessel disease. Besides, proteomics and transcriptomics studies found that the molecules that are significantly altered in CADASIL are mainly related to cell adhesion, the cytoskeleton or extracellular matrix components, misfolding control, autophagia, angiogenesis, or the transforming growth factor β (TGFβ) signaling pathway. The omics studies performed on CADASIL have been useful for understanding the biological mechanisms and could be key factors for finding potential drug targets.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rp11-362k2.2:Rp11-767i20.1 genetic variation is associated with post-reperfusion therapy parenchymal hematoma. a gwas meta-analysis

  • Muiño, Elena|||0000-0001-5839-7328
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Carrera, Caty|||0000-0002-0804-0969
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cullell, Natalia|||0000-0001-5118-1014
  • Lledós, Miquel|||0000-0001-8832-789X
  • Castillo, J.
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Campos, Francisco|||0000-0001-8665-1039
  • Rodríguez-Castro, E.
  • Millán, M.
  • Muñoz-Narbona, Lucia|||0000-0002-0884-3024
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • López-Cancio, E.
  • Ribó, M.
  • Álvarez Sabín, José|||0000-0002-8054-9209
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • Soriano-Tárraga, C.
  • Vives-Bauza, C.
  • Diaz-Navarro, Rosa
  • Tur, Silvia
  • Obach, Víctor|||0000-0002-0518-1053
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Segura, T.
  • Serrano-Heras, G.
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Guisado-Alonso, Daniel|||0000-0002-5799-3184
  • Guasch Jiménez, Marina|||0000-0001-6024-8348
  • Marín-Bueno, Rebeca|||0000-0002-0354-6602
  • Martínez-Domeño, Alejandro|||0000-0002-9933-3192
  • Freijo-Guerrero, M.D.M.
  • Moniche, F.
  • Cabezas, Juan Antonio
  • Castellanos, M.
  • Krupinsky, J.
  • Strbian, D.
  • Tatlisumak, T.
  • Thijs, V.
  • Lemmens, R.
  • Slowik, Agnieszka
  • Pera, J.
  • Heitsch, Laura
  • Ibañez, Laura
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Dhar, R.
  • Lee, J.M.
  • Montaner, J.
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Stroke is one of the most common causes of death and disability. Reperfusion therapies are the only treatment available during the acute phase of stroke. Due to recent clinical trials, these therapies may increase their frequency of use by extending the time-window administration, which may lead to an increase in complications such as hemorrhagic transformation, with parenchymal hematoma (PH) being the more severe subtype, associated with higher mortality and disability rates. Our aim was to find genetic risk factors associated with PH, as that could provide molecular targets/pathways for their prevention/treatment and study its genetic correlations to find traits sharing genetic background. We performed a GWAS and meta-analysis, following standard quality controls and association analysis (fastGWAS), adjusting age, NIHSS, and principal components. FUMA was used to annotate, prioritize, visualize, and interpret the meta-analysis results. The total number of patients in the meta-analysis was 2034 (216 cases and 1818 controls). We found rs79770152 having a genome-wide significant association (beta 0.09, p-value 3.90 × 10) located in the RP11-362K2.2:RP11-767I20.1 gene and a suggestive variant (rs13297983: beta 0.07, p-value 6.10 × 10) located in PCSK5 associated with PH occurrence. The genetic correlation showed a shared genetic background of PH with Alzheimer's disease and white matter hyperintensities. In addition, genes containing the ten most significant associations have been related to aggregated amyloid-β, tau protein, white matter microstructure, inflammation, and matrix metalloproteinases.
Dipòsit Digital de Documents de la UAB
Publicación

Metric learning for novelty and anomaly detection

  • Masana, Marc|||0000-0003-3254-3096
  • Ruiz López, Idoia|||0000-0003-0529-0871
  • Serrat, Joan|||0000-0002-4554-199X
  • Weijer, Joost van de|||0000-0002-9656-9706
  • López Peña, Antonio M.|||0000-0002-6979-5783
When neural networks process images which do not resemble the distribution seen during training, so called out-of-distribution images, they often make wrong predictions, and do so too confidently. The capability to detect out-of-distribution images is therefore crucial for many real-world applications. We divide out-of-distribution detection between novelty detection -images of classes which are not in the training set but are related to those-, and anomaly detection -images with classes which are unrelated to the training set. By related we mean they contain the same type of objects, like digits in MNIST and SVHN. Most existing work has focused on anomaly detection, and has addressed this problem considering networks trained with the cross-entropy loss. Differently from them, we propose to use metric learning which does not have the drawback of the softmax layer (inherent to cross-entropy methods), which forces the network to divide its prediction power over the learned classes. We perform extensive experiments and evaluate both novelty and anomaly detection, even in a relevant application such as traffic sign recognition, obtaining comparable or better results than previous works.
Dipòsit Digital de Documents de la UAB
Publicación Capítulo o parte de un libro (BookPart)

Rotate your networks, better weight consolidation and less catastrophic forgetting

  • Liu, Xialei
  • Masana, Marc|||0000-0003-3254-3096
  • Herranz, Luis|||0000-0002-7022-3395
  • Weijer, Joost van de|||0000-0002-9656-9706
  • López Peña, Antonio M.|||0000-0002-6979-5783
  • Bagdanov, Andrew|||0000-0001-6408-7043
In this paper we propose an approach to avoiding catastrophic forgetting in sequential task learning scenarios. Our technique is based on a network reparameterization that approximately diagonalizes the Fisher Information Matrix of the network parameters. This reparameterization takes the form of a factorized rotation of parameter space which, when used in conjunction with Elastic Weight Consolidation (which assumes a diagonal Fisher Information Matrix), leads to significantly better performance on lifelong learning of sequential tasks. Experimental results on the MNIST, CIFAR-100, CUB-200 and Stanford-40 datasets demonstrate that we significantly improve the results of standard elastic weight consolidation, and that we obtain competitive results when compared to the state-of-the-art in lifelong learning without forgetting.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Polygenic Risk Score Based on a Cardioembolic Stroke Multitrait Analysis Improves a Clinical Prediction Model for This Stroke Subtype

  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Muiño, Elena|||0000-0001-5839-7328
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cullell, Natalia|||0000-0001-5118-1014
  • Lledós, Miquel|||0000-0001-8832-789X
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Campos, Francisco|||0000-0001-8665-1039
  • Castillo, José
  • Freijo, Marimar
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Obach, Víctor|||0000-0002-0518-1053
  • Álvarez Sabín, José|||0000-0002-8054-9209
  • Molina, Carlos A.|||0000-0001-6058-6259
  • Ribo, Marc|||0000-0001-9242-043X
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Muñoz-Narbona, Lucia|||0000-0002-0884-3024
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Diaz-Navarro, Rosa
  • Vives-Bauza, Cristòfol
  • Serrano-Heras, Gemma|||0000-0001-9368-4832
  • Segura, Tomás|||0000-0003-3625-0987
  • Ibañez, Laura
  • Heitsch, Laura
  • Delgado, Pilar
  • Dhar, Rajat|||0000-0002-5167-5097
  • Krupinski, Jerzy|||0000-0002-5136-8898
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Blay, Natalia|||0000-0002-7160-8529
  • Sumoy, Lauro|||0000-0003-0005-4618
  • de Cid, Rafael|||0000-0003-3579-6777
  • Montaner, Joan|||0000-0003-4845-2279
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Lee, Jim-Moo
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Background: Occult atrial fibrillation (AF) is one of the major causes of embolic stroke of undetermined source (ESUS). Knowing the underlying etiology of an ESUS will reduce stroke recurrence and/or unnecessary use of anticoagulants. Understanding cardioembolic strokes (CES), whose main cause is AF, will provide tools to select patients who would benefit from anticoagulants among those with ESUS or AF. We aimed to discover novel loci associated with CES and create a polygenetic risk score (PRS) for a more efficient CES risk stratification. Methods: Multitrait analysis of GWAS (MTAG) was performed with MEGASTROKE-CES cohort (n = 362,661) and AF cohort (n = 1,030,836). We considered significant variants and replicated those variants with MTAG p-value < 5 × 10 influencing both traits (GWAS-pairwise) with a p-value < 0.05 in the original GWAS and in an independent cohort (n = 9,105). The PRS was created with PRSice-2 and evaluated in the independent cohort. Results: We found and replicated eleven loci associated with CES. Eight were novel loci. Seven of them had been previously associated with AF, namely, CAV1, ESR2, GORAB, IGF1R, NEURL1, WIPF1, and ZEB2. KIAA1755 locus had never been associated with CES/AF, leading its index variant to a missense change (R1045W). The PRS generated has been significantly associated with CES improving discrimination and patient reclassification of a model with age, sex, and hypertension. Conclusion: The loci found significantly associated with CES in the MTAG, together with the creation of a PRS that improves the predictive clinical models of CES, might help guide future clinical trials of anticoagulant therapy in patients with ESUS or AF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Altered methylation pattern in EXOC4 is associated with stroke outcome, an epigenome-wide association study

  • Cullell, Natalia|||0000-0001-5118-1014
  • Soriano Tárraga, Carolina|||0000-0002-5635-273X
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Muiño, Elena|||0000-0001-5839-7328
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Esteller, M.|||0000-0003-4490-6093
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Montaner, Joan|||0000-0003-4845-2279
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Delgado Martínez, María Pilar|||0000-0002-1628-4488
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Krupinski, Jerzy|||0000-0002-5136-8898
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Background and purpose: The neurological course after stroke is highly variable and is determined by demographic, clinical and genetic factors. However, other heritable factors such as epigenetic DNA methylation could play a role in neurological changes after stroke. Methods: We performed a three-stage epigenome-wide association study to evaluate DNA methylation associated with the difference between the National Institutes of Health Stroke Scale (NIHSS) at baseline and at discharge (ΔNIHSS) in ischaemic stroke patients. DNA methylation data in the Discovery (n = 643) and Replication (n = 62) Cohorts were interrogated with the 450 K and EPIC BeadChip. Nominal CpG sites from the Discovery (p value < 10) were also evaluated in a meta-analysis of the Discovery and Replication cohorts, using a random-fixed effect model. Metabolic pathway enrichment was calculated with methylGSA. We integrated the methylation data with 1305 plasma protein expression levels measured by SOMAscan in 46 subjects and measured RNA expression with RT-PCR in a subgroup of 13 subjects. Specific cell-type methylation was assessed using EpiDISH. Results: The meta-analysis revealed an epigenome-wide significant association in EXOC4 (p value = 8.4 × 10) and in MERTK (p value = 1.56 × 10). Only the methylation in EXOC4 was also associated in the Discovery and in the Replication Cohorts (p value = 1.14 × 10 and p value = 1.3 × 10, respectively). EXOC4 methylation negatively correlated with the long-term outcome (coefficient = - 4.91) and showed a tendency towards a decrease in EXOC4 expression (rho = - 0.469, p value = 0.091). Pathway enrichment from the meta-analysis revealed significant associations related to the endocytosis and deubiquitination processes. Seventy-nine plasma proteins were differentially expressed in association with EXOC4 methylation. Pathway analysis of these proteins showed an enrichment in natural killer (NK) cell activation. The cell-type methylation analysis in blood also revealed a differential methylation in NK cells. Conclusions: DNA methylation of EXOC4 is associated with a worse neurological course after stroke. The results indicate a potential modulation of pathways involving endocytosis and NK cells regulation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Genome-Wide Studies in Ischaemic Stroke, Are Genetics Only Useful for Finding Genes?

  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Muiño, Elena|||0000-0001-5839-7328
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Cullell, Natalia|||0000-0001-5118-1014
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Ischaemic stroke is a complex disease with some degree of heritability. This means that heritability factors, such as genetics, could be risk factors for ischaemic stroke. The era of genome-wide studies has revealed some of these heritable risk factors, although the data generated by these studies may also be useful in other disciplines. Analysis of these data can be used to understand the biological mechanisms associated with stroke risk and stroke outcome, to determine the causality between stroke and other diseases without the need for expensive clinical trials, or to find potential drug targets with higher success rates than other strategies. In this review we will discuss several of the most relevant studies regarding the genetics of ischaemic stroke and the potential use of the data generated.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The target antigen determines the mechanism of acquired resistance to T cell-based therapies

  • Morancho Armisen, Beatriz
  • Román Alonso, Macarena
  • Ovejero Romero, Pablo
  • Arribas López, Joaquin Vicente
  • Arenas Lahuerta, Enrique Javier
  • Martínez-Sabadell, Alex
  • Rius Ruiz, Irene
  • Escorihuela Baez, Marta
Cancer; Antigen; Resistance, Cáncer; Antígeno; Resistencia, Càncer; Antigen; Resistència, Despite the revolution of immunotherapy in cancer treatment, patients eventually progress due to the emergence of resistance. In this scenario, the selection of the tumor antigen can be decisive in the success of the clinical response. T cell bispecific antibodies (TCBs) are engineered molecules that include binding sites to the T cell receptor and to a tumor antigen. Using gastric CEA+/HER2+ MKN45 cells and TCBs directed against CEA or HER2, we show that the mechanism of resistance to a TCB is dependent on the tumor antigen. Acquired resistant models to a high-affinity-CEA-targeted TCB exhibit a reduction of CEA levels due to transcriptional silencing, which is reversible upon 5-AZA treatment. In contrast, a HER2-TCB resistant model maintains HER2 levels and exhibit a disruption of the interferon-gamma signaling. These results will help in the design of combinatorial strategies to increase the efficacy of cancer immunotherapies and to anticipate and overcome resistances., This work was supported by Asociación Española Contra el Cancer (AECC), Breast Cancer Research Foundation (BCRF-21-008), and Instituto de Salud Carlos III (PI19/01181). A.M.S. was funded by the Spanish Government (PFIS FI20/00188). B.M. was funded by a fellowship from PERIS (Departament de Salut, Generalitat de Catalunya). M.R.A. was funded by Agency for Management of University and Research Grants (AGAUR, 2022 FI_B2 00080). P.O.R. was funded by the BBVA. E.J.A. was funded by the AECC (POSTD211413AREN). VHIO acknowledges the Cellex Foundation for providing research facilities and equipment, the Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) from the Institute of Health Carlos III (ISCIII), and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 SLT008/18/00205) for their support on this research. The authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S/AEI/10.13039/501100011033) and for the Cancer Immunology and Immunotherapy (CAIMI-2) program funded by BBVA Foundation. We would like to remark the funding from B.M PERIS (Spain). The authors thank Dr. Anne Freimoser-Grundschober and Roche for helping provide the TCBs. The graphical abstract was created with BioRender.com.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Genome-wide transcriptome study in skin biopsies reveals an association of E2F4 with cadasil and cognitive impairment

  • Maisterra Santos, Olga
  • Jimenez Balado, Joan
  • Carrera, Caty
  • Torres‑Aguila, Nuria P.
  • Muiño, Elena
  • Cullell, Natalia
Demència; Mal de cap; Ictus, Demencia; Dolor de cabeza; Ictus, Dementia; Headache; Stroke, CADASIL is a small vessel disease caused by mutations in NOTCH3 that lead to an odd number of cysteines in the EGF-like repeat domain, causing protein misfolding and aggregation. The main symptoms are migraine, psychiatric disturbances, recurrent strokes and dementia, being executive function characteristically impaired. The molecular pathways altered by this receptor aggregation need to be studied further. A genome-wide transcriptome study (four cases paired with three healthy siblings) was carried out, in addition to a qRT-PCR for validation purposes (ten new cases and eight new controls). To study the expression profile by cell type of the significant mRNAs found, we performed an in situ hybridization (ISH) (nine cases and eight controls) and a research in the Single-nuclei Brain RNA-seq expression browser (SNBREB). Pathway analysis enrichment was carried out with Gene Ontology and Reactome. Neuropsychological tests were performed in five of the qRT-PCR cases. The two most significant differentially expressed mRNAs (BANP, p-value = 7.23 × 10–4 and PDCD6IP, p-value = 8.36 × 10–4) were selected for the validation study by qRT-PCR. Additionally, we selected two more mRNAs (CAMK2G, p-value = 4.52 × 10–3 and E2F4, p-value = 4.77 × 10–3) due to their association with ischemic neuronal death. E2F4 showed differential expression in the genome-wide transcriptome study and in the qRT-PCR (p = 1.23 × 10–3), and it was upregulated in CADASIL cases. Furthermore, higher E2F4 expression was associated with worse executive function (p = 2.04 × 10–2) and attention and information processing speed (IPS) (p = 8.73 × 10–2). In situ hibridization showed E2F4 expression in endothelial and vascular smooth vessel cells. In silico studies indicated that E2F4 is also expressed in brain endothelial cells. Among the most significant pathways analyzed, there was an enrichment of vascular development, cell adhesion and vesicular machinery terms and autophagy process. E2F4 is more highly expressed in the skin biopsy of CADASIL patients compared to controls, and its expression is present in endothelial cells and VSMCs. Further studies are needed to understand whether E2F4 could be useful as a biomarker, to monitor the disease or be used as a therapeutic target., This work was supported by a grant from the Carlos III Health Institute (PI 11/0176), Generación Project, Maestro Project, INVICTUS + network, Epigenesis Project (Marató de TV3), FEDER funds and economic donations from “Asociación CADASIL España”. E. Muiño is supported by a Río Hortega Contract (CM18/00198) from the Carlos III Health Institute. J. Cárcel-Márquez is supported by an AGAUR Contract (agència de gestió d'ajuts universitaris i de recerca; FI_DGR 2019, grant number 2019_FI_B 00853) co-financed with Fons Social Europeu (FSE). M. Lledós is supported by a PFIS Contract (Contratos Predoctorales de Formación en Investigación en Salud) from the Carlos III Health Institute.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

  • Ros Montañá, Fco. Javier
  • Fernández, Jose
  • Moreno-Cárdenas, Ana Belén
  • Arenillas Lallana, Carlota
  • Fasani, Roberta
  • Garcia Rodriguez, Ariadna
  • Gonzalo-Ruiz, Javier
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Pérez López, Raquel
  • Tabernero, Josep
  • De Almeida Toledo, Rodrigo
  • Comas Navarro, Raquel
  • Dienstmann, Rodrigo
  • Bernatowicz, Kinga
  • Piris-Giménez, Alejandro
  • Elez Fernandez, Mª Elena
  • Villacampa Javierre, Guillermo
Colorectal cancer; Predictive markers; Tumour biomarkers, Cáncer colorrectal; Marcadores predictivos; Biomarcadores tumorales, Càncer colorrectal; Marcadors predictius; Biomarcadors tumorals, Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients., VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the FERO Foundation for their funding support, the Consorcio Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, CB16/12/00259) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation, and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 and SLT008/18/00205) for their support on this research. Authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S / AEI / 10.13039 /501100011033). This research is funded by the SCITRON program; Novartis funded the genomics characterization by WES of samples from 28 patients from the discovery cohort and had no influence on data analysis/interpretation or writing of the paper (3003145512 to R.A.T.). S.Li. is financially supported by a Chinese Scholarship Council PhD fellowship (201909370083 to S. Li). R.P.-L. is supported by a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019 to R.P.-L.) and the Prostate Cancer Foundation (Young Investigator Award). This work was supported by the Miguel Servet-I Research Award from ISCIII of the Ministry of Economy (CP17/00199 to R.A.T.), the Olga Torres Foundation Award to emerging researchers (2601 to R.A.T.), the ISCIII-FEDER (PI17/00947 and PI20/00968 to E.E.), and the Fundación AECC (CLSEN19001ELEZ to E.E.) and Ministry of Science and Innovation (Europa Redes y Gestores, ECT2020-000827 to E.E.).